Tag: Cancer: Kidney
ASCO: Adding Atezolizumab to Cabozantinib No Benefit in Advanced Renal Cancer
No improvement seen in disease progression or death, and increase seen in serious adverse events with atezolizumab + cabozantinib
Cabozantinib Plus Nivolumab and Ipilimumab Increases PFS in Renal Cell Cancer
Progression-free survival significantly longer with addition of cabozantinib in previously untreated advanced renal cell carcinoma
Urothelial Cancer Prediction Model Has High Sensitivity, Specificity
Model, which considers 10 genes from UroAmp uCGP test, had high sensitivity and specificity in two validation cohorts
UGN-101 Reviewed in Real-World Upper Tract Urothelial Cancer Setting
For patients with low-grade residual disease, complete response rate was 70 percent with UGN-101
Trends in Genitourinary Cancers Examined in the United States
Among non-Hispanic Whites, highest incidence rates seen in Northeast for bladder cancer, Appalachia for kidney cancer
Cryoablation More Effective for Some Early-Stage Renal Cell Carcinomas
Increased cancer-specific mortality seen with heat-based thermal ablation versus cryoablation for tumor size 3.1 to 4 cm
Patients Favor Single-Port Robotic System for Uro-Oncology Surgery
Patients in the single-port versus multiport system group reported better cosmetic appearance, higher satisfaction with cosmetic appearance of surgical scar
Triplet Therapy Ups Progression-Free Survival in Advanced Kidney Cancer
PFS improved with cabozantinib + nivolumab + ipilimumab for patients with previously untreated advanced renal cell carcinoma
Adjuvant Nivolumab + Ipilimumab Lacks Efficacy for Localized RCC
Trial did not meet primary efficacy end point of disease-free survival in patients with localized RCC at high risk for postnephrectomy relapse
Treatments Compared for Advanced Renal Cell Carcinoma
Treatment-free survival more than twice as long for nivolumab plus ipilimumab versus sunitinib for intermediate/poor-risk patients
